Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Strong Doubts About PSA Testing

By HospiMedica staff writers
Posted on 22 Sep 2004
Following a study showing that the prostate-specific antigen (PSA) test as a screen indicates nothing more than the size of the prostate gland, researchers have declared that the test is all but useless for predicting cancer risk.

In the study, the researchers looked at prostate tissues collected over 20 years and found that the PSA test is actually not a useful predictor of the amount or severity of prostate cancer. More...
Elevated levels of PSA instead reflect benign prostatic hyperplasia, a harmless increase in prostate size.

"The PSA era is over in the United States,” said lead author Thomas Stamey, M.D., professor of urology at Stanford University School of Medicine (Palo Alto, CA, USA; www.med.stanford.edu). "Our study raises a very serious question of whether a man should even use the PSA test for prostate cancer screening anymore.” The new findings are to appear in the October 2004 issue of the Journal of Urology.

Dr. Stamey noted that the tumors encountered 20 years ago were generally so large they generated PSA levels high enough to provide a reasonably good measure of cancer severity. Now that screening is more commonplace, many cancers are being caught earlier and are usually smaller--not generating enough PSA to be a good indicator of severity. Still, the American Cancer Society estimates that nearly a quarter of a million cases of prostate cancer will be diagnosed in the United States alone this year, and one in six men will be diagnosed with the disease at some point in their lives.

However, the risk of dying from prostate cancer is very low compared with lung cancer, for example. Only 226 men out of every 100,000 over the age of 65 dies of prostate cancer, which is a rate of 0.003%.

Men whose PSA levels are above 2 ng/ml frequently undergo biopsy, which will almost always find cancer, but this does not necessarily mean that prostate removal or radiation treatment is required. "What we didn't know in the early years is that benign growth of the prostate is the most common cause of a PSA level between 1 and 10 ng/ml,” noted Dr. Stamey.

Dr. Stamey pointed out that the PSA test is still very useful for monitoring patients following prostate removal as an indicator of residual prostate cancer that has spread to other parts of the body. "Our job is to stop removing every man's prostate who has prostate cancer. Some men need prostate treatment but certainly not all of them.”

This raises the question of what, then, is the best course for detecting prostate cancer? Dr. Stamey recommends a yearly digital rectal exam for all men over 50. "If a cancer is felt in the prostate during a rectal examination, it is always a significant cancer and certainly needs treatment.” Unfortunately, even large cancers often cannot be felt during a rectal exam. Dr. Stamey and colleagues are working on finding a blood marker that could indicate more aggressive forms of the cancer that can invade the body.




Related Links:
Stanford U. School of Medicine

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.